Drug Trial Radar · NCT05726292
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jan 6, 2025
Primary completion
Oct 1, 2027
Study completion Apr 1, 2028
Sponsor
- Lead sponsor
- University of ChicagoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.
Conditions
- Prostate Cancer
- Prostate Adenocarcinoma
Interventions
RelacorilantDrug
Relacorilant is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is being used in this study as an experimental drug combined with other treatments for prostate cancer.
EnzalutamideDrug
Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen medication which is used in the treatment of prostate cancer.
Placebo (Sugar Pill)Other
This would be a sugar pill consisting of 2 softgels. This is not an experimental drug or treatment.
Androgen Deprivation TherapyOther
All participants in this study, who meet the requirements to participate, will get Androgen Deprivation Therapy (ADT; a form of hormone therapy) continuously before their radical prostatectomy surgery. As part of this study, ADT consists of one injection every 1-3 months. In this study, ADT is a gonadotropin releasing hormone (GnRH) agonists or antagonist; the choice of which brand of ADT to use is up to your treating physician. GnRH agonists and antagonists are drugs that lower the production of androgens (male hormones) in your body. Prostate cancer cells usually require androgens, such as testosterone, to grow. Androgen Deprivation Therapy (ADT) has been approved by United Stated Food and Drug Administration (US FDA) to treat patients with prostate cancer but is not approved to treat patients prior to prostatectomy.
Radical ProstatectomyProcedure
Radical prostatectomy is surgery to remove the entire prostate gland and surrounding lymph nodes to treat men with localized prostate cancer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response Rate of Subjects Receiving Relacorilant with Enzalutamide and Hormone TherapyTime frame: 24 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Recruiting
Endeavor Health
Evanston, Illinois · Not yet recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.